Non-obstructive Hypertrophic Cardiomyopathy: Clinical Trials

5 trials for Non-obstructive Hypertrophic Cardiomyopathy, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed, 1 recruiting. 5 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 25Completed 4, Recruiting 1
Phase 31Completed 1

Follow Non-obstructive Hypertrophic Cardiomyopathy: new trials by email Literature Review of Non-obstructive Hypertrophic Cardiomyopathy trials Research Report on Non-obstructive Hypertrophic Cardiomyopathy

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy
Ninerafaxstat 200mg MR, Placebo - Non-obstructive Hypertrophic Cardiomyopathy
Phase 2RecruitingImbria Pharmaceuticals, Inc.1652025-10-062026-10-26
A Phase II Clinical Study of HRS-1893 in Non-obstructive Hypertrophic Cardiomyopathy
HRS-1893, HRS-1893 placebo - Non-obstructive Hypertrophic Cardiomyopathy
Phase 2CompletedShandong Suncadia Medicine Co., Ltd.842025-02-252026-08-24
A Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Non-obstructive Hypertrophic Cardiomyopathy Trial
IMB-1018972, Placebo - Non-obstructive Hypertrophic Cardiomyopathy
Phase 2CompletedImbria Pharmaceuticals, Inc.672021-06-142024-04-23
A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM
mavacamten - Hypertrophic Cardiomyopathy, Obstructive Hypertrophic Cardiomyopathy
Phase 2 / Phase 3CompletedBristol-Myers Squibb3142018-09-272026-02-20
A Phase 2 Study of Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)
mavacamten, Placebo - Non-obstructive Hypertrophic Cardiomyopathy
Phase 2CompletedMyoKardia, Inc.592018-03-302022-08-09

Narrower conditions

Cardiomyopathy, Hypertrophic (2)

Broader conditions

Aortic Stenosis, Subvalvular (2)  ·  Aortic Valve Disease (2)  ·  Aortic Valve Stenosis (2)  ·  Cardiomyopathies (2)  ·  Cardiovascular Diseases (2)  ·  Heart Diseases (2)  ·  Heart Valve Diseases (2)

Interventions

MYK-461 (2)

Sponsors

Imbria Pharmaceuticals, Inc. (2)  ·  Bristol-Myers Squibb (1)  ·  MyoKardia, Inc. (1)  ·  Shandong Suncadia Medicine Co., Ltd. (1)

Countries

United States (4)  ·  United Kingdom (3)  ·  Belgium (2)  ·  France (2)  ·  Germany (2)  ·  Italy (2)  ·  Netherlands (2)  ·  Poland (2)  ·  Portugal (2)  ·  Spain (2)  ·  Austria (1)  ·  China (1)  ·  Czechia (1)  ·  Denmark (1)  ·  Israel (1)

Results publications

PMID 32466879, PMID 38176782, PMID 39217450, PMID 42636950